BACKGROUND: Breast cancer has traditionally been considered to have a low immunogenic potential compared to other tumor entities. SUMMARY: The most extensively studied immunotherapeutic agents for breast cancer to date are immune checkpoint inhibitors, with the results of the IMpassion130 trial leading to the approval of atezolizumab plus nab-paclitaxel for first-line treatment of programmed cell death ligand 1-positive, metastatic, triple-negative breast cancer, and studies in earlier stages have yielded promising results. Other immunotherapeutic options being assessed in phases 2 and 3 trials include vaccine-based therapies and treatment with anti-human epidermal growth factor receptor 2 (H-directed immune-linked antibodies) and substances evaluated in early clinical trials as cellular therapies (adoptive cell therapy and chimeric antigen receptor T cells). KEY MESSAGES: Immunotherapy is an emerging modality for the treatment of breast cancer, as evidenced by the plethora of preclinical and clinical concepts and ongoing trials. Early studies established the role of immunotherapeutic agents in the metastatic setting. Ongoing studies will expand our knowledge about the timing of administration, best partners for combination therapy, and predictive biomarkers to guide immunotherapy for breast cancer.
BACKGROUND: Breast cancer has traditionally been considered to have a low immunogenic potential compared to other tumor entities. SUMMARY: The most extensively studied immunotherapeutic agents for breast cancer to date are immune checkpoint inhibitors, with the results of the IMpassion130 trial leading to the approval of atezolizumab plus nab-paclitaxel for first-line treatment of programmed cell death ligand 1-positive, metastatic, triple-negative breast cancer, and studies in earlier stages have yielded promising results. Other immunotherapeutic options being assessed in phases 2 and 3 trials include vaccine-based therapies and treatment with anti-human epidermal growth factor receptor 2 (H-directed immune-linked antibodies) and substances evaluated in early clinical trials as cellular therapies (adoptive cell therapy and chimeric antigen receptor T cells). KEY MESSAGES: Immunotherapy is an emerging modality for the treatment of breast cancer, as evidenced by the plethora of preclinical and clinical concepts and ongoing trials. Early studies established the role of immunotherapeutic agents in the metastatic setting. Ongoing studies will expand our knowledge about the timing of administration, best partners for combination therapy, and predictive biomarkers to guide immunotherapy for breast cancer.
Authors: Sherene Loi; Anita Giobbie-Hurder; Andrea Gombos; Thomas Bachelot; Rina Hui; Giuseppe Curigliano; Mario Campone; Laura Biganzoli; Hervé Bonnefoi; Guy Jerusalem; Rupert Bartsch; Manuela Rabaglio-Poretti; Roswitha Kammler; Rudolf Maibach; Mark J Smyth; Angelo Di Leo; Marco Colleoni; Giuseppe Viale; Meredith M Regan; Fabrice André Journal: Lancet Oncol Date: 2019-02-11 Impact factor: 41.316
Authors: David Miles; Henri Roché; Miguel Martin; Timothy J Perren; David A Cameron; John Glaspy; David Dodwell; Joanne Parker; José Mayordomo; Alejandro Tres; James Lee Murray; Nuhad K Ibrahim Journal: Oncologist Date: 2011-05-14
Authors: Xiangnan Guan; Kyle M LaPak; Rebecca C Hennessey; Christina Y Yu; Reena Shakya; Jianying Zhang; Christin E Burd Journal: Mol Cancer Res Date: 2016-12-30 Impact factor: 5.852
Authors: Patrick G Gavin; Nan Song; S Rim Kim; Corey Lipchik; Nicole L Johnson; Hanna Bandos; Melanie Finnigan; Priya Rastogi; Louis Fehrenbacher; Eleftherios P Mamounas; Sandra M Swain; D Lawrence Wickerham; Charles E Geyer; Jong-Hyeon Jeong; Joseph P Costantino; Norman Wolmark; Soonmyung Paik; Kay L Pogue-Geile Journal: JAMA Oncol Date: 2017-03-01 Impact factor: 31.777
Authors: Liya Ding; Hye-Jung Kim; Qiwei Wang; Michael Kearns; Tao Jiang; Carolynn E Ohlson; Ben B Li; Shaozhen Xie; Joyce F Liu; Elizabeth H Stover; Brooke E Howitt; Roderick T Bronson; Suzan Lazo; Thomas M Roberts; Gordon J Freeman; Panagiotis A Konstantinopoulos; Ursula A Matulonis; Jean J Zhao Journal: Cell Rep Date: 2018-12-11 Impact factor: 9.423
Authors: Franklin Mayca Pozo; Xinran Geng; Ilaria Tamagno; Mark W Jackson; Ernest G Heimsath; John A Hammer; Richard E Cheney; Youwei Zhang Journal: Sci Adv Date: 2021-09-15 Impact factor: 14.136